Metformin was superior in reducing A1C values in previously untreated type 2 diabetes

초기 당뇨병 단독 치료로 메트포민을 먼저 사용하다가

​

혈당조절이 안되어 2번째 약제를 추가한 경우가 많다 보니

​

원래 메트포민 단독 치료로 어짜피 원하는 당화혈색소 수치에 도달하지 못할 환자였음에도

​

메트포민 효능이 약해서 다른 약이 필요한 착각에 빠지는 경우가 있습니다.

DPP4억제제가 메트포민보다 효능이 강할 것 같은?

 

빌다글립틴 (가브스정) 50 mg [하루 2회]와 메트포민 1000 mg [하루 2회] 중에 어느 것이 더 효능이 강할까요?

​

In studies of previously untreated patients, vildagliptin had similar A1C-lowering efficacy as rosiglitazone but was less effective than metformin. As an example, in a 52-week noninferiority study of vildagliptin (100 mg daily) versus metformin (titrated to 2000 mg daily) in 780 patients with previously untreated type 2 diabetes, metformin was superior (vildagliptin was not found to be noninferior) in reducing A1C values (between-group difference 0.4 percentage points, 95% CI 0.28-0.65). Goal A1C (<7.0 percent) was achieved by 45 and 35 percent of those who received metformin and vildagliptin, respectively.

​

​

REF. UpToDate 2020.07.01